JPWO2021134086A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021134086A5 JPWO2021134086A5 JP2022539383A JP2022539383A JPWO2021134086A5 JP WO2021134086 A5 JPWO2021134086 A5 JP WO2021134086A5 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP WO2021134086 A5 JPWO2021134086 A5 JP WO2021134086A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorders
- anxiety
- depression
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 208000020401 Depressive disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000019022 Mood disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000011117 substance-related disease Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025029197A JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953611P | 2019-12-26 | 2019-12-26 | |
| US62/953,611 | 2019-12-26 | ||
| US202063037044P | 2020-06-10 | 2020-06-10 | |
| US63/037,044 | 2020-06-10 | ||
| US202063093830P | 2020-10-20 | 2020-10-20 | |
| US63/093,830 | 2020-10-20 | ||
| PCT/US2020/067235 WO2021134086A1 (en) | 2019-12-26 | 2020-12-28 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025029197A Division JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023508469A JP2023508469A (ja) | 2023-03-02 |
| JP2023508469A5 JP2023508469A5 (https=) | 2023-12-20 |
| JPWO2021134086A5 true JPWO2021134086A5 (https=) | 2023-12-20 |
| JP7644122B2 JP7644122B2 (ja) | 2025-03-11 |
Family
ID=74195194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539383A Active JP7644122B2 (ja) | 2019-12-26 | 2020-12-28 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
| JP2025029197A Pending JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025029197A Pending JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11344510B2 (https=) |
| EP (1) | EP4081301A1 (https=) |
| JP (2) | JP7644122B2 (https=) |
| KR (1) | KR20220131520A (https=) |
| CN (2) | CN115190815B (https=) |
| AU (1) | AU2020415511A1 (https=) |
| CA (1) | CA3165903A1 (https=) |
| IL (1) | IL294202A (https=) |
| MX (1) | MX2022007994A (https=) |
| WO (1) | WO2021134086A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN115190815B (zh) * | 2019-12-26 | 2024-06-18 | 吉尔伽美什制药公司 | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 |
| KR20230124103A (ko) | 2020-02-18 | 2023-08-24 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| CA3220228A1 (en) | 2021-05-25 | 2022-12-01 | Celia MORGAN | Ketamine in the treatment of behavioural addictions |
| CA3225353A1 (en) * | 2021-06-25 | 2022-12-29 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
| AU2022374097A1 (en) * | 2021-10-18 | 2024-03-14 | Clearmind Labs Corp. | 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression |
| WO2023154450A2 (en) * | 2022-02-11 | 2023-08-17 | Gilgamesh Pharmaceuticals, Inc. | (ampa-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders |
| CN115677444A (zh) * | 2022-10-26 | 2023-02-03 | 公安部第三研究所 | 同位素毒品代谢物标记化合物及其制备方法、用途 |
| AU2023419893A1 (en) * | 2022-12-28 | 2025-07-03 | Gilgamesh Pharmaceuticals, Inc. | Synthesis of 2-phenyl-2-amino-cyclohexan-1-one derivatives |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| KR20260018914A (ko) * | 2023-06-05 | 2026-02-09 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 2-페닐-2-아미노시클로헥산-1-온 유도체의 결정성 염 |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB853775A (en) | 1957-09-19 | 1960-11-09 | Parke Davis & Co | Pharmaceutical compositions and methods for producing phenylcyclohexane compounds |
| DE1668550A1 (de) * | 1967-09-19 | 1971-07-22 | Parke Davis & Co | 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung |
| CA1105938A (en) | 1976-06-03 | 1981-07-28 | Daniel Lednicer | 4-amino-4-arylcyclohexanone ketals |
| US4065573A (en) | 1976-06-03 | 1977-12-27 | The Upjohn Company | 4-Amino-4-phenylcyclohexanone ketal compositions and process of use |
| CA1100516A (en) | 1976-06-03 | 1981-05-05 | Daniel Lednicer | 4-amino-4-arylcyclohexanones and their ketals |
| AU2003249584B9 (en) | 2002-06-21 | 2008-05-15 | Suven Life Sciences Limited | Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| AU2003249583B2 (en) | 2002-06-21 | 2007-06-07 | Suven Life Sciences Limited | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| BR0312176A (pt) | 2002-06-21 | 2005-04-05 | Suven Life Sciences Ltd | Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10252666A1 (de) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| DE10360793A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1912970A2 (en) | 2005-08-10 | 2008-04-23 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| EP1956016A1 (en) | 2006-12-15 | 2008-08-13 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CN102046591B (zh) | 2008-03-27 | 2014-12-03 | 格吕伦塔尔有限公司 | 羟甲基环己胺 |
| EP2385944A4 (en) | 2009-01-09 | 2013-06-19 | Harvard College | FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF |
| WO2010136546A1 (en) | 2009-05-27 | 2010-12-02 | Université Libre de Bruxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| CN104276993B (zh) | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| GB201808150D0 (en) | 2018-05-18 | 2018-07-11 | Small Pharma Ltd | Therapeutic compounds |
| GB201716942D0 (en) | 2017-10-16 | 2017-11-29 | Small Pharma Ltd | Therapeutic compounds |
| MA50786A (fr) | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| EP3505509A1 (en) | 2017-12-29 | 2019-07-03 | Université de Liège | Methods for the preparation of arylcycloalkylamine derivatives |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN110343050B (zh) | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| KR102104953B1 (ko) * | 2018-04-17 | 2020-04-27 | 삼육대학교 산학협력단 | 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도 |
| TW202026281A (zh) | 2018-12-12 | 2020-07-16 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物 |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| CN115190815B (zh) * | 2019-12-26 | 2024-06-18 | 吉尔伽美什制药公司 | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 |
| CN112174851A (zh) | 2020-11-09 | 2021-01-05 | 广州万孚生物技术股份有限公司 | 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用 |
| CN113234036B (zh) | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
-
2020
- 2020-12-28 CN CN202080097657.8A patent/CN115190815B/zh active Active
- 2020-12-28 IL IL294202A patent/IL294202A/en unknown
- 2020-12-28 AU AU2020415511A patent/AU2020415511A1/en active Pending
- 2020-12-28 EP EP20845344.9A patent/EP4081301A1/en active Pending
- 2020-12-28 JP JP2022539383A patent/JP7644122B2/ja active Active
- 2020-12-28 CN CN202410706398.4A patent/CN119241381A/zh active Pending
- 2020-12-28 MX MX2022007994A patent/MX2022007994A/es unknown
- 2020-12-28 KR KR1020227025076A patent/KR20220131520A/ko active Pending
- 2020-12-28 CA CA3165903A patent/CA3165903A1/en active Pending
- 2020-12-28 WO PCT/US2020/067235 patent/WO2021134086A1/en not_active Ceased
-
2021
- 2021-10-25 US US17/510,108 patent/US11344510B2/en active Active
-
2022
- 2022-04-06 US US17/714,879 patent/US20220409555A1/en active Pending
-
2025
- 2025-02-26 JP JP2025029197A patent/JP2025090628A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021134086A5 (https=) | ||
| DE60029139T2 (de) | Bupropion metabolite und verfahren zur deren synthese und verwendung | |
| JP2012521994A5 (https=) | ||
| IL255433B2 (en) | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine | |
| JP2019507781A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2022191257A5 (https=) | ||
| JP2010138190A5 (https=) | ||
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| CA2470956A1 (en) | 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists | |
| WO2004060882A1 (en) | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | |
| JP2021513975A5 (https=) | ||
| JP2009527462A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2013530953A5 (https=) | ||
| JP2013526596A5 (https=) | ||
| JP6426302B2 (ja) | ３−［（ベンゾ［ｄ］［１，３］ジオキソラン−４−イル）−オキシ］−３−アリールプロピルアミン型化合物およびその適用 | |
| JP2018530608A5 (https=) | ||
| JPWO2017131149A1 (ja) | テトラヒドロナフタレン誘導体 | |
| US5055468A (en) | Use of bridged tricyclic amine derivatives as anti-ischemic agents | |
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| JPH06500099A (ja) | Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用 | |
| JP2007530703A5 (https=) | ||
| JPWO2022221227A5 (https=) | ||
| JP2007529492A5 (https=) |